Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Watch Twitter or Facebook for updates.
Yes, I strongly believe we will be at new highs. Ohio clinics are in great shape. Robert and Adam are busting their butts. They have accomplished a lot in a short time spanned, roughly one year.
I hope you are right on Porky. We could use a good solid run to offset such obvious manipulation. Those selling their shares at these prices are going to be very mad at themselves when this takes off and they have to pay 10 times the amount for the same amount of shares they just had. See this type of thing all of the time.
would sure be nice to get an update -
from PAOG. at least a few crumbs thrown our way ?
LONG and STRONG- PAOG $$$$$$$
Thanks again. Place PAOG on your radar. Revenues should be much higher this quarter then last quarter.
UP 55% since last week $SGMD Analysis-comparison. Kush has 60mn shares times about $3. Give $180 market value. They did $18 million. That 10x revenues. If Sugarmade does $45 million that’s a $450. mm market value. Divide that by about a billion shares and we get $0.45. #MJ #Cannabis #He
PAOG Rally will probably happen before.
I still say JANUARY will be -
our month. looking for .10-.20 cents to hit.
GO PAOG $$$$$$$$$$$$$$$
its time for PAOG-
to start making some moves UP-
many MMJ SECTOR STOCKS are on FIRE-
Biotech Market Banking on Big Cannabis Returns
Date :
12/19/2017 @ 8:45AM
Biotech Market Banking on Big Cannabis Returns
CannabisNewsWire Editorial Coverage: Relatively insulated from economic cycles, the innovation of today’s biotech companies puts them in a position to potentially deliver outsized returns regardless of overall conditions. Medicinal cannabis, a key sector in this industry, is currently driving the largest returns, and it is on pace to exceed US$50 billion in revenues by 2025. As more investors are noticing, positive news continues to flow into the sector in terms of new drug applications, product approvals and pipeline updates. For InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), a preclinical-stage biopharmaceutical company at the vanguard of cannabinoid-based bio-pharmacology, market awareness of the company’s drug development pipeline and biosynthesis technology has led to gains of more than 400% over the last year. This level of activity places InMed, currently valued at $100 million, among the ranks of larger cannabis biotechs like GW Pharma (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF).
Backed by mounting scientific data on the curative effects of CBDs, specialty biotech companies have the opportunity to capitalize on the explosive growth expected in the cannabis-derived pharmaceutical market. The discovery of the human endocannabinoid system dramatically changed both the understanding and the vast potential of cannabinoid therapeutics, and thus has increased acceptance and awareness of the potential of cannabinoids to affect a much broader range of physiological functions than previously considered. With a tsunami of innovation, cannabinoid pharmaceutical companies now research, identify and develop new drug candidates to create unique therapeutics to treat multiple maladies and unmet medical needs.
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) market traction is based on the company’s proprietary cannabinoid biosynthesis technology, one of three of its core assets and one which serves as the base for its development of its drug-development pipeline of novel therapeutics that leverage the pharmacological benefits of cannabinoids like CBD. As TheSeedInvestor.com asked in a recent article, could InMed be the “next big thing in cannabis?” (http://cnw.fm/JS9lv).
To date, most CBD research and drug development has focused on the most easily isolated CBDs, but multiple curative opportunities are believed to be found in the other 90+ cannabinoids of the marijuana plant. InMed is the only known company with the ability to isolate and bio-identically manufacture all of the naturally occurring CBDs found in the cannabis sativa plant (http://cnw.fm/5BfmB).
Conducted in-house, InMed’s cost-effective biosynthesis process enhances the production, purification and quality control compared to other chemical manufacturing methods, such as chemical synthesis. InMed’s ability to produce its own pharmaceutical grade, bio-identical CBDs also sets it apart from other companies that rely on outside cultivators for their product supply.
In September, InMed filed a provisional patent to protect its biosynthesis program (http://cnw.fm/B7PDd). Once the patent application is converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, InMed will have significant commercial protection of its technology as it explores the various ways it could have a medical impact on important human diseases. Release of the patent filing sent shares of InMed from $0.27 at market open to an intra-day high of $0.40 a day later – with volume increasing roughly 8-fold to over 2.1 million for two consecutive days. Shares of InMed trading on the U.S. OTC market have continued to climb and just recently clipped a new 52-week high of $0.86.
It’s important to note that InMed’s market gains hinge on more than its biosynthesis program. The company’s portfolio of biomedical assets also includes a proprietary bioinformatics assessment tool that enables the high-efficiency prediction of the therapeutic potential and medicinal properties of individual CBDs against particular medical conditions.
This computer-assisted system employs comprehensive algorithms to integrate data from various bioinformatics databases, including a vast database of the chemical structures of approved pharmaceuticals, with InMed’s proprietary cannabinoid database and know-how. This assessment tool, in combination with the company’s biosynthesis technology and drug development pipeline, provides InMed a competitive advantage and serves as its fundamental value driver for drug discovery.
This unparalleled approach to cannabinoid production, research and targeted drug development could be a game-changer for the market, as many drug development efforts with synthetic derivatives have failed. InMed’s production of CBDs identical to naturally occurring compounds has already led to a growing pipeline of potentially blockbuster drug candidates.
The company is currently developing two products in its drug pipeline headed for clinical trials; INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma. Additionally, the company continues to advance its INM-405 candidate for the treatment of chronic and severe pain.
InMed’s INM-750 for Epidermolysis Bullosa, an orphan disease characterized by extremely fragile skin, has potential global market revenues estimated at $1 billion per year. Another candidate in the pipeline, INM-085 for Glaucoma, has a global market potential in excess of $5 billion, and the company’s development of INM-405 targets the $36+ billion pain market.
In October, InMed provided an update on its pain program with additional pre-clinical results suggesting that peripheral application of certain CBD compounds, either alone or in combination, is effective in the treatment of craniofacial muscle pain disorders without any observed side effects to the central nervous system (http://nnw.fm/1Os9A). With increased pressure for the pharma industry to find non-addictive pain management alternatives with limited side effects, InMed continues to research the potential of non-THC cannabinoids to treat pain using a topical formulation.
Leveraging its proprietary technologies, InMed is rapidly expanding its pipeline of novel cannabinoid therapeutics for a variety of medical conditions. Historically, biotech companies are valued at about three times the peak annual sales of a company's lead candidate. With a market cap around $100 million, InMed may be significantly undervalued based on its capabilities.
Researching and developing cannabinoids for medical use since 1998 is cannabis biotech leader GW Pharma (NASDAQ: GWPH). Focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas, GW Pharma has only identified 15 of the 90+ CBDs in the cannabis plant, as noted by TheSeedInvestor.com, and yet currently occupies a market cap of over $3 billion.
GW Pharma commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. The company has submitted an NDA to the FDA for its leading development candidate, Epidiolex, a formulation for the treatment of childhood-onset epilepsy disorders like Lennox-Gastaut syndrome and Dravet syndrome. The company also has several other product candidates in development for treating glioblastoma, schizophrenia and epilepsy.
TheSeedInvestor.com also points out that Dr. Ado Muhammed, chief medical officer of InMed and previously the associate medical director at GW Pharmaceuticals, was instrumental in leading GW Pharma when shares rose from less than $9 in 2013 to more than $130 today.
Another biotech cannabis leader is Zynerba Pharmaceuticals (NASDAQ: ZYNE), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments. Zynerba’s ZYN002 CBD gel is the first and only pharmaceutically produced CBD formulated as a patent-protected permeation-enhanced gel and is being studied in children with Fragile X Syndrome, adult epilepsy patients with focal seizures and osteoarthritis. Currently trading around $12, shares of Zynerba have ranged from $5.42-$25.95 over the last year, and the company has a market valuation in excess of $160 million.
Trading between $9 and $28.50 over the last year with a market cap near $430 million, Cara Therapeutics (NASDAQ: CARA) is a clinical-stage biotech company looking to change how pain is treated. Its portfolio includes opioid-based products, anesthetic-based drugs and analgesics that seek to alleviate itch and pain. Cara is developing a new class of medicine called Kappa Opioid Receptor Agonists (KORAs). KORAs target a completely different receptor in the body, the kappa opioid receptor, to treat pain in a fundamentally new way. The company’s lead pipeline product, CR845, is a peripherally acting KORAs. To date, CR845 has shown in phase 2 clinical trials promising pain relief without many of the traditional side effects of opioids and NSAIDs.
Isodiol International (CSE: ISOL) (OTC: ISOLF) is a leader in pharmaceutical and nutraceutical grade phytochemical (plant-based) compounds and an industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is one of the world’s largest sources for phyto-cannabinoids and offers high quality, bioactive products from seed to finished product. Isodiol was one of the first to commercialize 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations and nanotechnology for high quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and continued international expansion. Trading around $1.15 per share, Isodiol has a 52-week range of $0.05 to $1.69 and carries $380+ million market capitalization.
Historically, the biotechnology sector has been volatile but it also has delivered some of the market’s greatest returns. Cannabinoid biotechs now lead the way in the sector and, as research continues, a myriad of compounds may soon be developed to unlock a vast range of new therapeutics that could benefit millions of ailing people. New-found cannabinoid therapeutics have the potential to create a bonanza in the biotech sector and early investors could reap extraordinary returns.
As more investors plot their way through biotech opportunities, an increasing number of them recognize the potential value of cannabis-focused contenders like InMed pursuing ways to apply CBDs to treat unmet medical needs.
yes..
any good info will do
paog/rsii
I'm not asking for exact numbers an estimate is fine with most of us here.
indeed
forward him this site also
I'm sure Robert knows a close estimates of this quarter revenues. He may release those findings sooner. It would be are great Christmas gift.
My guess is we wait till 2018 for news...just a guess.
PAOG
Thanks for the heads up.
$SGMD BudLife $$$$$$$ $36 Million in REVENUE$
New$ Coming on SGMD - Largest Publicly Traded MJ Company, we will see the pps run into the high teen$$$$$$
Sugarmade to Become the World's Largest Publicly Traded Cannabis Industry Supply Company
https://www.otcmarkets.com/stock/SGMD/news/Sugarmade-to-Become-the-World-s-Largest-Publicly-Traded-Cannabis-Industry-Supply-Company?id=178317&b=y
wow you guys are really loading
good luck
easy 10 c in time
yes Maronti beach is big enough for all the longs here
I got that 375000 lot and another lot around 200000....:)
PAOG
I figure when PAOG goes to 10 cents or higher I can buy a car to travel on Maronti.
great addition to your stack
we all should be rewarded in time
paog a no brainer!"
PAOG...Just added 250,000.
I believe we may see something on PAOG twitter account. It's been almost two months.
again looks like the same investor or group selling paog/rsii
geez management..get a grip
and release a nice pr on both
I dont think so Maronti ...I think there are only 2 spots..
PAOG
I will be there for sure!
would be a fantastic trip and a dream to see you and all longs come and jump in the warm waters of Maronti's beach
when paog hits 20/30/50c
paog/rsii
Agreed. My buy order is filling!
There is no reason why PAOG PPS isn't a dime. MJNA is over 10 cents and their share structure is 4.5 times higher than PAOG.
I'll take that...
PAOG
Robert Weber is ahead of the game in Ohio. My hunch revenues will be at least 50 percent higher then it was last quarter. Great growth.
I agree. I've been adding to my position for the past 3 months. Retirement on Maronti island.
Absolutely, Ohio laws are changing rapidly in favor of MJ use.
PAOG about to be slammed with everyone wanting in. Looking to a great year here.
time for updates on the new openings
time for ending the downturn
our time coming
paog
RSII and PAOG...Good Video explains what Medical MJ Clinics and Dispenseries are all about. ...Medical Marijuana For My Chronic Pain
GROOVE- I agree- PAOG-
is gonna FLY in 2018. MJ MANIA IS ABOUT TO HIT THE MJ STOCK SECTOR, and PAOG will PROSPER HUGE from it.
GO PAOG $$$$
GOOD LUCK TO ALL US LONGS $$$$$$$$
2018 really smells big..I appreciate your posts Porky...
PAOG
you have to love what this company is doing-
AND its the "perfect storm"- they are in the right business, with the current opioid crisis in this country. many people are still saying we will be the next owc$, and I must agree. we are all very fortunate to be in on the "ground -floor opportunity of a lifetime" with PAOG. Patience will pay off HUGE here.
PAOG= BUY-ACCUMUALTE-HOLD = HUGE $$$$$$
groovemaster- thank you- AWESOME JOB -
on the IBOX! ITS MUCH APPRECIATED BY ALL HERE.
also- it will help out a lot of new investors for PAOG $$$
the next 2 weeks leading into the start of CALIFORNIA REC. MJ legalization is already creating a lot of "chatter" in the MJ SECTOR, and stocks like POAG will definitely be on the radars .
GOOD LUCK TO YOU AND ALL OF US PAOG LONGS $$$
GO PAOG !!!
LOOKING FORWARD TO A VERY PROSPEROUS 2018 $$$
Ok Porky.....I edited the Ibox....check it out. I have been working on it since you posted....LOL The videos were a challenge as they kept disappearing every time I edited. I think I have all the videos up there that were created....actually quite interesting listening to them again.
PAOG
found this also by google it
http://www.awetv.com/miraclecure/
i just ran into a tv show by coincidence
very interesting
(Marijuna Miracle Cure 3)
PAOG IS A "ONE-OF-A-KIND" MMJ STOCK-
and it will soon be discovered by the masses. gotta wonder how much money all those new "bitcoin millionaires " will be pouring into PAOG ?? I imagine quite a bit of new money $$$$
GO PAOG $$$$$$$$$$$$
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
134
|
Created
|
12/15/17
|
Type
|
Free
|
Moderator GrooveMaster | |||
Assistants timetomakemoney |
Market Value1 | $4,616,193 | a/o Dec 15, 2017 | |
Authorized Shares | 985,000,000 | a/o Jun 30, 2017 | |
Outstanding Shares | 710,183,464 | a/o Jun 30, 2017 | |
-Restricted | Not Available | ||
-Unrestricted | Not Available | ||
Held at DTC | Not Available | ||
Float | 549,183,464 | a/o Jul 12, 2017 | |
Par Value | 0.001 |
Posts Today
|
0
|
Posts (Total)
|
134
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |